SP 21
Relapsed and refractory classical Hodgkin lymphoma immunotherapy
Kirill Lepik
Lido
2535
Vezesque se leu este artigo
1059
Total PDF
1476
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 24 | 11 | 35 |
| 2025 5 | 51 | 13 | 64 |
| 2025 4 | 46 | 13 | 59 |
| 2025 3 | 52 | 16 | 68 |
| 2025 2 | 25 | 14 | 39 |
| 2025 1 | 41 | 19 | 60 |
| 2024 12 | 29 | 16 | 45 |
| 2024 11 | 38 | 16 | 54 |
| 2024 10 | 21 | 18 | 39 |
| 2024 9 | 82 | 25 | 107 |
| 2024 8 | 28 | 27 | 55 |
| 2024 7 | 26 | 17 | 43 |
| 2024 6 | 27 | 27 | 54 |
| 2024 5 | 31 | 21 | 52 |
| 2024 4 | 24 | 18 | 42 |
| 2024 3 | 26 | 15 | 41 |
| 2024 2 | 30 | 24 | 54 |
| 2024 1 | 27 | 23 | 50 |
| 2023 12 | 31 | 22 | 53 |
| 2023 11 | 41 | 34 | 75 |
| 2023 10 | 27 | 25 | 52 |
| 2023 9 | 36 | 35 | 71 |
| 2023 8 | 23 | 9 | 32 |
| 2023 7 | 34 | 6 | 40 |
| 2023 6 | 18 | 18 | 36 |
| 2023 5 | 25 | 14 | 39 |
| 2023 4 | 14 | 1 | 15 |
| 2023 3 | 25 | 16 | 41 |
| 2023 2 | 16 | 13 | 29 |
| 2023 1 | 18 | 9 | 27 |
| 2022 12 | 23 | 17 | 40 |
| 2022 11 | 15 | 14 | 29 |
| 2022 10 | 18 | 14 | 32 |
| 2022 9 | 24 | 26 | 50 |
| 2022 8 | 17 | 21 | 38 |
| 2022 7 | 19 | 17 | 36 |
| 2022 6 | 9 | 17 | 26 |
| 2022 5 | 16 | 19 | 35 |
| 2022 4 | 18 | 17 | 35 |
| 2022 3 | 20 | 19 | 39 |
| 2022 2 | 25 | 17 | 42 |
| 2021 1 | 13 | 13 | 26 |
| 2021 12 | 13 | 21 | 34 |
| 2021 11 | 22 | 28 | 50 |
| 2021 10 | 33 | 23 | 56 |
| 2021 9 | 23 | 24 | 47 |
| 2021 8 | 22 | 31 | 53 |
| 2021 7 | 16 | 25 | 41 |
| 2021 6 | 17 | 22 | 39 |
| 2021 5 | 36 | 34 | 70 |
| 2021 4 | 55 | 30 | 85 |
| 2021 3 | 35 | 21 | 56 |
| 2021 2 | 22 | 15 | 37 |
| 2020 1 | 17 | 17 | 34 |
| 2020 12 | 5 | 9 | 14 |
| 2020 11 | 7 | 13 | 20 |
Mostrar tudo
